NovaBridge Biosciences (NBP) Profit After Tax (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Profit After Tax of $103.8 million for Q4 2025, up 208.85% year-over-year from $33.6 million in Q4 2024, and up 1620.53% quarter-over-quarter from -$6.8 million in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Profit After Tax (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Profit After Tax for 5 consecutive years, with $103.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax rose 208.85% year-over-year to $103.8 million; the TTM figure through Dec 2025 stood at $88.3 million (up 297.39% YoY), while the FY2025 annual figure was $88.3 million, up 297.39% from the prior year.
- Profit After Tax rose to $103.8 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $103.8 million in Q4 2025 and bottomed at -$347.6 million in Q4 2023.
- Historically, Profit After Tax has averaged -$31.4 million across 3 years, with a median of -$6.8 million in 2025.
- On a YoY basis, Profit After Tax climbed as much as 208.85% in 2025 and fell as far as 121.65% in 2025.
- NovaBridge Biosciences' Profit After Tax stood at -$347.6 million in 2023, then jumped by 109.67% to $33.6 million in 2024, then soared by 208.85% to $103.8 million in 2025.
- Business Quant data shows NBP's Profit After Tax at $103.8 million in Q4 2025, -$6.8 million in Q3 2025, and -$5.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -16.62 Mn |
| 10 | NovaBridge Biosciences | 199.88 Mn | 199.88 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 16.62 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | 25.42 Mn |
| Mar 31, 2024 | -16.32 Mn |
| Dec 31, 2023 | -67.90 Mn |
| Sep 30, 2023 | -46.80 Mn |
| Jun 30, 2023 | -61.47 Mn |
| Dec 31, 2020 | 157.16 Mn |
| Sep 30, 2020 | 1.77 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -34.39 Mn |